Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate + camrelizumab
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a multi-agent chemotherapy and immunotherapy combination used primarily in clinical trials for advanced gastrointestinal cancers, notably pancreatic cancer. The regimen includes: - **Liposomal Irinotecan**: A topoisomerase I inhibitor encapsulated in a liposome to enhance delivery and reduce toxicity. - **Oxaliplatin**: A platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. - **5-Fluorouracil**: An antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Calcium Folinate (Leucovorin)**: Enhances the efficacy of 5-fluorouracil by stabilizing its binding to thymidylate synthase. - **Camrelizumab**: A monoclonal antibody targeting PD‑1, acting as an immune checkpoint inhibitor. The combination aims to maximize cytotoxic effects on tumor cells while leveraging immune modulation. It is being investigated for borderline resectable pancreatic cancer and other solid tumors[1][2][4].
- Other names
- FOLFIRIFOLFOXIRI
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate + camrelizumab.